Rockwell Medical to Report Third Quarter 2020 Financial and Operating Results on November 9, 2020

Rhea-AI Summary

Rockwell Medical, a biopharmaceutical company, will host a conference call on November 9, 2020, at 4:30 p.m. ET, to discuss its financial results for Q3 2020 and recent operational developments. Interested participants can join by dialing (877) 383-7438 for local access or (678) 894-3975 for international access, with a conference ID of 7679074. The call will also be available via live webcast. Rockwell Medical specializes in iron deficiency treatments for patients with end-stage kidney disease through its FDA-approved products, Triferic Dialysate and Triferic AVNU.

WIXOM, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, November 9, 2020, at 4:30 p.m. ET to discuss its financial results for the three months ended September 30, 2020, and recent operational highlights.

To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 7679074. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

To submit questions in advance, please email your questions to invest@rockwellmed.com.

About Rockwell Medical

Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company’s initial focus is the treatment of anemia in end-stage kidney disease (ESKD). Rockwell Medical's exclusive renal drug therapies, Triferic® (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

About Triferic Dialysate and Triferic AVNU

Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management – with the potential to become the future standard of care.

Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to the bone marrow and maintain hemoglobin without increasing iron stores (ferritin). Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body) upon entry into the blood which is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no reports of anaphylaxis in over 1,200,000 patient administrations, addressing a significant medical need in overcoming Functional Iron Deficiency (FID) in ESKD patients.

Important Safety Information

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving Triferic in two randomized clinical trials.

Iron status should be determined on pre-dialysis blood samples. Post dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

The most common adverse reactions (≥3% and at least 1% greater than placebo) in controlled clinical studies include: procedural hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%), asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

FAQ

What is the date and time of Rockwell Medical's conference call regarding Q3 2020 results?

Rockwell Medical's conference call will take place on November 9, 2020, at 4:30 p.m. ET.

How can I access the conference call by Rockwell Medical?

To access the conference call, dial (877) 383-7438 for local calls or (678) 894-3975 for international calls, and refer to conference ID 7679074.

Where can I find the archived webcast of Rockwell Medical's conference call?

The archived webcast will be available on Rockwell Medical's website approximately two hours after the call and will be accessible for 30 days.

What is Triferic and its significance for patients?

Triferic is an FDA-approved therapy by Rockwell Medical that replaces iron and maintains hemoglobin levels in hemodialysis patients, addressing iron deficiency effectively.

What are the potential side effects associated with Triferic?

Common side effects of Triferic include procedural hypotension, muscle spasms, headaches, and fatigue, among others.